On March 31, 2018, Wuhan Life Origin Biotech and 2013 Nobel Laureate in Physiology or Medicine, Academician of the National Academy of Sciences, and Professor Randy Schekman of the University of California, Berkeley, were in Wuhan East Lake New Technology Development Zone. A signing ceremony was held in the press conference hall of Building 4 of the Public Service Center to jointly build a Nobel Prize Workstation. In this cooperation, Professor Randy Schekman will serve as the chief academic advisor of Wuhan Life Origin Biotech, and provide technical guidance for us. The two parties will invite other units to jointly apply for national major scientific research on the topic of "vesicle diagnostic research and industrialization". subject, and jointly complete the subject research.

Feng Li, Chief Engineer of Donghu High-tech Zone Management Committee, Qian Deping, Executive Deputy Director of Wuhan National Bio-Industry Base Construction Management Office, Yu Bo, Minister of Industry Department of Wuhan High-Tech State-owned Holding Group Co., Ltd., and General Manager of Medical Device Park Company attended the signing ceremony. Witness the historic moment of Wuhan Life Origin Biotech together.

The topic of this collaboration is based on Professor Randy Schickman's discovery of the regulation mechanism of vesicle transport, the main intracellular transport system is extremely important for many physiological processes in which vesicles are involved. Bubble fusion must be controlled, including signaling in the brain and the release of hormones and immune factors. Defective vesicle trafficking occurs in many diseases, including a number of neurological and immune diseases, diabetes, skin diseases, tumors, and others. Research on the mechanism of action of vesicles, development of corresponding diagnostic markers and in vitro diagnostic kits will be helpful for the early diagnosis, diagnosis and precision medicine of various diseases. Wuhan Life Origin Biotech is a national high-tech enterprise dedicated to the research of clinical in vitro diagnostic products for a long time. After years of development, the company has built a leading biochemical product research and development platform, latex enhanced product research and development platform, and POCT diagnostic product platform. Deploy a number of high-end diagnostic product platforms such as chemiluminescence diagnostic platforms and molecular diagnostic platforms. With the company's good technical advantages and platform support, in 2015, it was approved to set up a "post-doctoral scientific research station" to better improve the technical platform and develop high-quality products. On the existing technology platform, Wuhan Life Origin Biotech will cooperate with Professor Randy Schickman, the Nobel Prize winner in the field of vesicle research, and jointly explore the early diagnosis of vesicles by virtue of Professor Schickman's accumulation of basic technologies in vesicle research. Development of markers and corresponding in vitro diagnostic kits to promote research and industrialization in the field of vesicle diagnostics.

We have reasons to believe that with the introduction of new technologies and good policies, Wuhan Life Origin Biotech will continue to pioneer innovation in the diagnostic field, develop more advantageous projects to meet market demand while promoting its own good development.